Anti-Cancer and Immunomodulating agents Flashcards
A nucleoside analog that is enzymatically converted by deoxycytidine kinase (dCK) to its active form, the 5′-monophosphate ribonucleotide is
A - leucovorin.
B - 5-fluorouracil (5-FU).
C - azacytidine.
D - gemcitabine.
E - cytarabine (Ara-C).
E - cytarabine (Ara-C).
When administered prior to 5-FU, this agent enhances the activation of and antitumor activity by increasing pools of PRPP.
A - Leucovorin
B - Oxaliplatin
C - Methotrexate
D - Cytarabine (Ara-C)
E - Fluxuridine
C - Methotrexate
An enzyme derived from Escherichia coli that deprives leukemia cells of a required amino acid is
A - pentostatin.
B - L-asparaginase (L-ASP).
C - deoxycytidine kinase (dCK).
D - trabectedin.
E - asparagine synthase.
B - L-asparaginase (L-ASP).
Paclitaxel and the other taxanes have a central role in the therapy of ovarian, breast, lung, GI, genitourinary, and head and neck cancers. The cytotoxic effect of the taxanes in tumor cells is the result of
A - inhibition of microtubule formation.
B - inhibition of microtubule disassembly.
C - enhancement of microtubule disassembly.
D - inhibition of topoisomerase I.
E - inhibition of topoisomerase II.
B - inhibition of microtubule disassembly.
The camptothecins, topotecan and irinotecan, are potent, cytotoxic neoplastic agents. They act by
A - intercalating DNA.
B - alkylating DNA.
C - stabilizing the DNA-topoisomerase I cleavable complex.
D - inhibiting DNA cleavage by topoisomerase I.
E - inhibiting topoisomerase I binding to DNA.
C - stabilizing the DNA-topoisomerase I cleavable complex.
An important mechanism by which clinical resistance develops to imatinib in chronic myelogenous leukemia is
A - increased excretion in the urine.
B - increased hepatic metabolism.
C - decreased bioactivation in cancer cells.
D - spontaneous mutations in the BCR-ABL kinase.
E - increased efflux from tumor cells.
D - spontaneous mutations in the BCR-ABL kinase
The molecular target of trastuzumab is
A - BCR-ABL.
B - VEGF.
C - ErbB1.
D - ErbB2.
E - CD20.
D - ErbB2
Rituximab is approved as a single agent for relapsed indolent lymphomas. Its molecular target is
A - the CD20 antigen on B cells.
B - the CD52 antigen on B cells.
C - the CD33 antigen on B cells and other hematopoietic cells.
D - BCR-ABL in lymphoblasts.
E - the IL-2 receptor on T cells.
A - the CD20 antigen on B cells
Which of the following agents kills multiple myeloma (MM) cells by indirectly preventing the transcriptional activity of NF-κB?
A - Thalidomide
B - Lenalidomide
C - Bortezomib
D - Sorafenib
E - Sirolimus
C - Bortezomib
Aldesleukin is approved for use in metastatic renal-cell cancer and metastatic melanoma. Its mechanism of action in treating these cancers is to
A - antagonize IL-2 receptors on T cells.
B - antagonize IL-2 receptors on epithelial cells.
C - stimulate the proliferation of activated T cells.
D - stimulate the proliferation of activated B cells.
E - inhibit the secretion of cytokines by immune effector cells.
C - stimulate the proliferation of activated T cells
A woman being treated for breast cancer develops
numbness and tingling in her hands and feet. Which
drug most likely caused this adverse effect?
(A) cyclophosphamide
(B) docetaxel
(C) doxorubicin
(D) tamoxifen
(E) trastuzumab
(B) docetaxel
Which adverse effect may result from cisplatin therapy?
(A) cardiac toxicity
(B) liver failure
(C) muscle toxicity
(D) nephrotoxicity
(E) hemolytic anemia
(D) nephrotoxicity
A woman with chronic myeloid leukemia responds to
imatinib therapy as indicated by a cytologic remission.
Which enzyme is inhibited by this drug?
(A) DNA polymerase
(B) dihydrofolate reductase
(C) BCR-ABL tyrosine kinase
(D) thymidylate synthetase
(E) hypoxanthine guanine phosphoribosyltransferase
(C) BCR-ABL tyrosine kinase
Which type of cancer is treated with trastuzumab if the
cells overexpress human epidermal growth factor
receptors?
(A) breast cancer
(B) ovarian cancer
(C) non-Hodgkin lymphoma
(D) multiple myeloma
(E) melanoma
(A) breast cancer
Which immunosuppressant drug forms a complex with
the FK-binding protein, resulting in inhibition of
calcineurin and T lymphocyte activation?
(A) cyclosporine
(B) prednisone
(C) cyclophosphamide
(D) tacrolimus
(E) azathioprine
(D) tacrolimus
